Medicare local coverage
Medicare coverage for MolDX: Phenotypic Biomarker Detection in Circulating Tumor Cells (LCD)
One Medicare Administrative Contractor, Palmetto GBA, publishes a local coverage determination (LCD) for MolDX: Phenotypic Biomarker Detection in Circulating Tumor Cells. The snapshot lists 1 LCD record: 1 active.
An LCD applies only in the jurisdiction of the contractor that wrote it. Two contractors can cover the same service with different criteria, documentation requirements and covered diagnoses, so check the LCD from the contractor that processes your claims.
LCDs by contractor
| Contractor | LCD | Status | Last updated |
|---|---|---|---|
Palmetto GBAMAC - Part A, MAC - Part B | L38566 | Active | Jun 24, 2025 |
An LCD marked Future has been finalized and is in its notice period; it applies from the effective date shown. LCD IDs link to the record on cms.gov.
Check claim lines against Medicare coverage
Coverage Check tells you whether a claim's diagnoses support Medicare LCD or NCD coverage for each procedure line, and shows the policy and CMS source behind each answer.
Related LCD topics
- MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
- Automated Detection and Quantification of Brain MRIs
- Bladder/Urothelial Tumor Markers
- Cardiac Event Detection
- Lab: Bladder/Urothelial Tumor Markers
- MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
All Medicare LCD topics · National coverage determinations · Payer policies by payer
Source: CMS Medicare Coverage Database, via the public CMS Coverage API, snapshot Oct 25, 2026. LCDs change between snapshots; confirm the version in effect for your date of service on cms.gov before billing.